ReviewJournal of fungi (Basel, Switzerland)2019
Identification of Mycoses in Developing Countries.
Review in Journal of fungi (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 61 citations in OpenAlex.
- Candiduria in catheterized ICU patients: epidemiology, molecular identification, and antifungal susceptibility.Iranian journal of microbiology · 2026Article
- Can We Have Guidelines or Just Guidance for Rare Fungal Infections?Journal of fungi (Basel, Switzerland) · 2025Article
- An Optimized In-House Protocol forJournal of fungi (Basel, Switzerland) · 2025Article
- Genetic Epidemiology and Resistance Investigations of Clinical Yeasts in Alexandria, Egypt.Pathogens (Basel, Switzerland) · 2025Article
- Article
- Recent Challenges in Diagnosis and Treatment of Invasive Candidiasis in Neonates.Children (Basel, Switzerland) · 2024Review
- Epidemiology of Candidemia in Mashhad, Northeast Iran: A Prospective Multicenter Study (2019-2021).Journal of fungi (Basel, Switzerland) · 2024Article
- Assessing Diagnosis ofJournal of fungi (Basel, Switzerland) · 2024Article
- Clinical Implementation ofJournal of fungi (Basel, Switzerland) · 2023Article
- A Comprehensive Review of Identification Methods for Pathogenic Yeasts: Challenges and Approaches.Advanced biomedical research · 2023Review
- Ten decadal advances in fungal biology leading towards human well-being.Fungal diversity · 2022Review
- Morphologic identification of clinically encountered moulds using a residual neural network.Frontiers in microbiology · 2022Article
- Determinants of fluconazole resistance and the efficacy of fluconazole and milbemycin oxim combination againstFrontiers in fungal biology · 2022Article
- Comparison of PCR-RFLP with 21-plex PCR and rDNA Sequencing for Identification of Clinical Yeast Isolates.Mycopathologia · 2021Article
- Candidemia among Iranian Patients with Severe COVID-19 Admitted to ICUs.Journal of fungi (Basel, Switzerland) · 2021Article
- Investigation of the Emerging NosocomialFrontiers in microbiology · 2021Article
- Rapid Detection ofFrontiers in cellular and infection microbiology · 2021Article
- Clonal Candidemia Outbreak byFrontiers in cellular and infection microbiology · 2021Article
- A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women.Frontiers in microbiology · 2021Article
- Pervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive advances in technology offer a vast variety of diagnostic methods that save time and costs, but identification of fungal species causing human infections remains challenging in developing countries. Since the echinocandins, antifungals widely used to treat invasive mycoses, are still unavailable in developing countries where a considerable number of problematic fungal species are present, rapid and reliable identification is of paramount importance. Unaffordability, large footprints, lack of skilled personnel, and high costs associated with maintenance and infrastructure are the main factors precluding the establishment of high-precision technologies that can replace inexpensive yet time-consuming and inaccurate phenotypic methods. In addition, point-of-care lateral flow assay tests are available for the diagnosis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.